Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13

被引:11
作者
Agamennone, Mariangela [1 ]
Belov, Dmitry S. [2 ,4 ]
Laghezza, Antonio [3 ]
Ivanov, Vladimir N. [4 ]
Novoselov, Anton M. [4 ]
Andreev, Ivan A. [2 ,4 ]
Ratmanova, Nina K. [4 ]
Altieri, Andrea [2 ]
Tortorella, Paolo [3 ]
Kurkin, Alexander V. [4 ]
机构
[1] Univ G DAnnunzio, Dipartimento Farm, Via Vestini 31, I-66013 Chieti, Italy
[2] EDASA Sci Srls, Via Stingi 37, I-66050 San Salvo, Italy
[3] Univ Aldo Moro Bari, Dipartimento Farm Sci Farmaco, Via Orabona 4, I-70126 Bari, Italy
[4] Lomonosov Moscow State Univ, Dept Chem, GSP-2,Leninskie Gory 1-3, Moscow 119991, Russia
基金
俄罗斯基础研究基金会;
关键词
5-arylisatin; fragment-based screening; hit generation; inhibitors; matrix metalloproteinases; TISSUE INHIBITOR; DRUG-LIKE; CANCER; ACIDS; FUNCTIONALIZATION; INVASION; THERAPY; TARGET; MMP-2; SITE;
D O I
10.1002/cmdc.201600266
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Matrix metalloproteinases (MMPs) are well-established targets for several pathologies. In particular, MMP-2 and MMP-13 play a prominent role in cancer progression. In this study, a structure-based screening campaign was applied to prioritize metalloproteinase-oriented fragments. This computational model was applied to a representative fragment set from the publically available EDASA Scientific compound library. These fragments were prioritized, and the top-ranking hits were tested in a biological assay to validate the model. Two scaffolds showed consistent activity in the assay, and the isatin-based compounds were the most interesting. These latter fragments have significant potential as tools for the design and realization of novel MMP inhibitors. In addition to their micromolar activity, the chemical synthesis affords flexible and creative access to their analogues.
引用
收藏
页码:1892 / 1898
页数:7
相关论文
共 46 条
[1]   Fragmenting the S100B-p53 Interaction: Combined Virtual/Biophysical Screening Approaches to Identify Ligands [J].
Agamennone, Mariangela ;
Cesari, Lucia ;
Lalli, Daniela ;
Turlizzi, Elisa ;
Del Conte, Rebecca ;
Turano, Paola ;
Mangani, Stefano ;
Padova, Alessandro .
CHEMMEDCHEM, 2010, 5 (03) :428-435
[2]  
[Anonymous], 2014, CANV VERS 2 0 MAESTR
[3]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[4]   Fragment-based lead discovery grows up [J].
Baker, Monya .
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (01) :5-10
[5]   MMPs - Role in cardiovascular development and disease [J].
Brauer, PR .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 :447-478
[6]   Matrix metalloproteinases: Role in arthritis [J].
Burrage, PS ;
Mix, KS ;
Brinckerhoff, CE .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 :529-543
[7]   Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors [J].
Campestre, Cristina ;
Tortorella, Paolo ;
Agamennone, Mariangela ;
Preziuso, Serena ;
Biasone, Alessandro ;
Nuti, Elisa ;
Rossello, Amando ;
Gallina, Carlo .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (05) :1008-1014
[8]   Matrix metalloproteinases degrade myelin basic protein [J].
Chandler, S ;
Coates, R ;
Gearing, A ;
Lury, J ;
Wells, G ;
Bone, E .
NEUROSCIENCE LETTERS, 1995, 201 (03) :223-226
[9]  
Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4
[10]   Matrix metalloproteinase-2 as a target for head and neck cancer therapy [J].
Chien, Ming-Hsien ;
Lin, Chiao-Wen ;
Cheng, Chao-Wen ;
Wen, Yu-Ching ;
Yang, Shun-Fa .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (02) :203-216